drugset / Trial / NCT04740970

A Study of JNJ-64304500 in Participants With Alopecia Areata

NCT04740970

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the clinical response of 22 weeks of study intervention with JNJ-64304500, compared with placebo, in participants with moderate to severe alopecia areata (AA).

Timeline

Start
2021-03-24
Primary completion
2022-06-02
Completion
2022-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64304500 Unknown Subcutaneous

Indications